Anavex Life Sciences Corp (AVXL)

[nidan7500]

Jimmy_Mcy...looks like they got some dates crossed...note 2023...???

https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.059024

Study of the mechanism of action of Blarcamesine (ANAVEX®2-73): Whole blood transcriptomics analysis identifies treatment impact on compensatory pathways by restoring key neurodegenerative pathways functionality, including Alzheimer’s disease pathway
Coralie Williams, Martin Kindermans, Frédéric Parmentier, Federico Goodsaid, Edward Hammond, Christopher U Missling, Mohammad Afshar
First published: 16 June 2023 https://doi.org/10.1002/alz.059024

Results
Blarcamesine significantly restores functionality in key pathways of Alzheimer’s disease, Parkinson’s disease and Prion diseases. The analysis identified two clusters of genes that are significantly differentially expressed in treated patients and represent compensatory pathways to genes dysregulations induced by neurodegenerative diseases. In both clusters, majority of genes were confirmed to interact (STRING database). Amongst interacting genes, neurodegenerative pathways were identified as overrepresented (p < 0.01). Down-regulation of genes involved with neurodegeneration was observed in the placebo arm, however, was compensated in the blarcamesine arm.

Conclusions
This analysis identified a gene network that is differentially expressed in patients treated with blarcamesine after 14 weeks of treatment, compared to placebo. The biological relevance of this gene network was assessed. Pathway analysis confirmed the impact of the treatment on pathways involved in neurodegenerative diseases The identification of a gene network as the blarcamesine response pathway lays the foundation to better understand the mechanism of action at the molecular level of blarcamesine, thus unlocking characterization of responders based on molecular profiling, as well as identification of new indications in the area of neurodegenerative and other disorders.